Surgery Partners (NASDAQ:SGRY – Get Free Report) and Amarantus Bioscience (OTCMKTS:AMBS – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.
Risk and Volatility
Surgery Partners has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Amarantus Bioscience has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Surgery Partners and Amarantus Bioscience, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surgery Partners | 1 | 3 | 7 | 0 | 2.55 |
| Amarantus Bioscience | 0 | 0 | 0 | 0 | 0.00 |
Valuation & Earnings
This table compares Surgery Partners and Amarantus Bioscience”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surgery Partners | $3.31 billion | 0.60 | -$77.90 million | ($0.70) | -21.83 |
| Amarantus Bioscience | N/A | N/A | N/A | N/A | N/A |
Amarantus Bioscience has lower revenue, but higher earnings than Surgery Partners.
Profitability
This table compares Surgery Partners and Amarantus Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surgery Partners | -2.63% | 0.87% | 0.34% |
| Amarantus Bioscience | N/A | N/A | N/A |
Summary
Surgery Partners beats Amarantus Bioscience on 7 of the 8 factors compared between the two stocks.
About Surgery Partners
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
About Amarantus Bioscience
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.
